- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Xenim
Cefepime
Description:
Cefepime (Xenim) is a fourth generation cephalosporin and is active against a wide range of gram-positive and gram-negative aerobic organisms. Against gram-positive cocci, its activity is similar to that of cefotaxime and includes staphylococci (but not methicillin-resistant Staphylococcus aureus) and streptococci. Against Enterobacteriaceae, it has a broader spectrum of activity than other cephalosporins, including activity against organisms producing chromosomally mediated beta-lactamases such as Enterobacter species and Proteus vulgaris.
Cefepime (Xenim) is a fourth generation cephalosporin and is active against a wide range of gram-positive and gram-negative aerobic organisms. Against gram-positive cocci, its activity is similar to that of cefotaxime and includes staphylococci (but not methicillin-resistant Staphylococcus aureus) and streptococci. Against Enterobacteriaceae, it has a broader spectrum of activity than other cephalosporins, including activity against organisms producing chromosomally mediated beta-lactamases such as Enterobacter species and Proteus vulgaris.
Indications:
Pneumonia (moderate to severe): caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Febrile neutropenia: Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying haematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. Uncomplicated and complicated urinary tract infections (including pyelonephritis): caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated skin and skin structure infections: caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes. Complicated intra-abdominal infections (used in combination with metronidazole): caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides tragilis.
Pneumonia (moderate to severe): caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Febrile neutropenia: Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying haematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. Uncomplicated and complicated urinary tract infections (including pyelonephritis): caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated skin and skin structure infections: caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes. Complicated intra-abdominal infections (used in combination with metronidazole): caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides tragilis.
Mode of Action:
Cefepime (Xenim ) inhibits bacterial cell wall synthesis and thus exerts bactericidal action.
Cefepime (Xenim ) inhibits bacterial cell wall synthesis and thus exerts bactericidal action.
Other Brands From Same Therapeutic Class
